Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Etanercept
Drug: Methotrexate
Drug: Placebo

First Posted Date: 2005-09-19

Last Posted Date: 2012-09-05

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 542

Registration Number: NCT00195494

A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Etanercept

First Posted Date: 2005-09-19

Last Posted Date: 2013-08-15

Lead Sponsor: Pfizer

Target Recruit Count: 1014

Registration Number: NCT00195403

Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain

Completed

Conditions: Rheumatoid Arthritis
Inflammation

First Posted Date: 2005-09-19

Last Posted Date: 2009-06-04

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 93

Registration Number: NCT00195364

Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Phase 4

Completed

Conditions: Psoriasis
Arthritis, Psoriatic

First Posted Date: 2005-09-12

Last Posted Date: 2009-09-28

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 60

Registration Number: NCT00161655

Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis

Phase 3

Completed

Conditions: Pediatric Plaque Psoriasis

Interventions: Drug: Etanercept

First Posted Date: 2005-09-02

Last Posted Date: 2017-10-05

Lead Sponsor: Amgen

Target Recruit Count: 182

Registration Number: NCT00141921

Study Evaluating Etanercept in Moderate to Severe Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2005-09-01

Last Posted Date: 2009-08-07

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 120

Registration Number: NCT00141791

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Phase 2

Completed

Conditions: Lung Injury, Acute
Respiratory Distress Syndrome, Adult
Bronchiolitis Obliterans

Interventions: Drug: Etanercept

First Posted Date: 2005-09-01

Last Posted Date: 2015-12-03

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 34

Registration Number: NCT00141726

Locations: 🇺🇸
The University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2

Completed

Conditions: Graft-Versus-Host Disease

Interventions: Drug: Etanercept

First Posted Date: 2005-09-01

Last Posted Date: 2017-01-30

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 100

Registration Number: NCT00141739

Locations: 🇺🇸
Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States